 BridgeBio Pharma Inc. BBIO, 5.84 said Monday that a Phase 3 study of its acoramidis for the treatment of symptomatic transthyretin TTR amyloid cardiomyopathy ATTR-CM failed to meet its primary endpoint at Month 12. The company said the decline observed in both arms of the study was similar to expected functional decline in healthy elderly adults, and were also substantially less than declines observed in previous untreated arms reviewed by the company. 